Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B

Molecular Therapy

Volumn 18, Issue 11, 2010, Pages 1896-1906

  Hausl, Martin A ^a   Zhang, Wenli ^a   Müther, Nadine ^a   Rauschhuber, Christina ^a   Franck, Helen G ^b   Merricks, Elizabeth P ^b   Nichols, Timothy C ^b   Kay, Mark A ^c   Ehrhardt, Anja ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9; LIVER ENZYME; SLEEPING BEAUTY PROTEIN; TRANSPOSASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TENDENCY; CELL CYCLE; CONTROLLED STUDY; DOG; FEMALE; GENE CASSETTE; GENE EXPRESSION; GENE VECTOR; HEMOPHILIA B; HEMOSTASIS; MOUSE; NONHUMAN; TOXICITY TESTING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA; CANIS FAMILIARIS; MAMMALIA; MUS;

EID: 78049463445     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.169     Document Type: Article

References (48)

1. Kay, MA, Rothenberg, S, Landen, CN, Bellinger, DA, Leland, F, Toman, C et al. (1993). In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-defcient dogs. Science 262: 117-119.
2. Brown, BD, Cantore, A, Annoni, A, Sergi, LS, Lombardo, A, Della Valle, P et al. (2007). A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 110: 4144-4152.
3. Vandendriessche, T, Thorrez, L, Acosta-Sanchez, A, Petrus, I, Wang, L, Ma, L et al. (2007). Effcacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 5: 16-24.
4. Niemeyer, GP, Herzog, RW, Mount, J, Arruda, VR, Tillson, DM, Hathcock, J et al. (2009). Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 113: 797-806.
5. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
6. Kay, MA, Landen, CN, Rothenberg, SR, Taylor, LA, Leland, F, Wiehle, S et al. (1994). In vivo hepatic gene therapy: complete albeit transient correction of factor IX defciency in hemophilia B dogs. Proc Natl Acad Sci USA 91: 2353-2357.
7. Yang, Y, Ertl, HC and Wilson, JM (1994). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1: 433-442.
8. Yang, Y, Xiang, Z, Ertl, HC and Wilson, JM (1995). Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 92: 7257-7261.
9. Yang, Y, Li, Q, Ertl, HC and Wilson, JM (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69: 2004-2015.
10. Amalftano, A, Hauser, MA, Hu, H, Serra, D, Begy, CR and Chamberlain, JS (1998). Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 72: 926-933.
11. Andrews, JL, Kadan, MJ, Gorziglia, MI, Kaleko, M and Connelly, S (2001). Generation and characterization of E1/E2a/E3/E4-defcient adenoviral vectors encoding human factor VIII. Mol Ther 3: 329-336.
12. Gorziglia, MI, Kadan, MJ, Yei, S, Lim, J, Lee, GM, Luthra, R et al. (1996). Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol 70: 4173-4178.
13. Parks, RJ, Chen, L, Anton, M, Sankar, U, Rudnicki, MA and Graham, FL (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 93: 13565-13570.
14. Parks, RJ and Graham, FL (1997). A helper-dependent system for adenovirus vector production helps defne a lower limit for effcient DNA packaging. J Virol 71: 3293-3298.
15. Brunetti-Pierri, N, Stapleton, GE, Palmer, DJ, Zuo, Y, Mane, V P, Finegold, MJ et al. (2007). Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther 15: 732-740.
16. Morral, N, Parks, RJ, Zhou, H, Langston, C, Schiedner, G, Quinones, J et al. (1998). High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α1-antitrypsin with negligible toxicity. Hum Gene Ther 9: 2709-2716.
17. Brunetti-Pierri, N, Palmer, DJ, Beaudet, AL, Carey, KD, Finegold, M and Ng, P (2004). Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15: 35-46.
18. Mane, VP, Toietta, G, McCormack, WM, Conde, I, Clarke, C, Palmer, D et al. (2006). Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of frst-generation and helper-dependent adenoviral vectors. Gene Ther 13: 1272-1280.
19. Muruve, DA, Cotter, MJ, Zaiss, AK, White, LR, Liu, Q, Chan, T et al. (2004). Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78: 5966-5972.
20. Ehrhardt, A and Kay, MA (2002). A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99: 3923-3930.
21. Kim, IH, Józkowicz, A, Piedra, PA, Oka, K and Chan, L (2001). Lifetime correction of genetic defciency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 98: 13282-13287.
22. Schiedner, G, Morral, N, Parks, RJ, Wu, Y, Koopmans, SC, Langston, C et al. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 18: 180-183.
23. Toietta, G, Mane, V P, Norona, WS, Finegold, MJ, Ng, P, McDonagh, AF et al. (2005). Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 102: 3930-3935.
24. Brunetti-Pierri, N, Stapleton, GE, Law, M, Breinholt, J, Palmer, DJ, Zuo, Y et al. (2009). Effcient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther 17: 327-333.
25. Ehrhardt, A, Xu, H, Dillow, AM, Bellinger, DA, Nichols, TC and Kay, MA (2003). A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 102: 2403-2411.
26. Brunetti-Pierri, N, Nichols, TC, McCorquodale, S, Merricks, E, Palmer, DJ, Beaudet, AL et al. (2005). Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum Gene Ther 16: 811-820.
27. Ohbayashi, F, Balamotis, MA, Kishimoto, A, Aizawa, E, Diaz, A, Hasty, P et al. (2005). Correction of chromosomal mutation and random integration in embryonic stem cells with helper-dependent adenoviral vectors. Proc Natl Acad Sci USA 102: 13628-13633.
28. Harui, A, Suzuki, S, Kochanek, S and Mitani, K (1999). Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 73: 6141-6146.
29. Stephen, SL, Sivanandam, VG and Kochanek, S (2008). Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J Gene Med 10: 1176-1189.
30. Yant, SR, Ehrhardt, A, Mikkelsen, JG, Meuse, L, Pham, T and Kay, MA (2002). Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 20: 999-1005.
31. Ivics, Z, Hackett, PB, Plasterk, RH and Izsvák, Z (1997). Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fsh, and its transposition in human cells. Cell 91: 501-510.
32. Yant, SR, Huang, Y, Akache, B and Kay, MA (2007). Site-directed transposon integration in human cells. Nucleic Acids Res 35: e50.
33. Jager, L, Hausl, MA, Rauschhuber, C, Wolf, NM, Kay, MA and Ehrhardt, A (2009). A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat Protoc 4: 547-564.
34. Palmer, D and Ng, P (2003). Improved system for helper-dependent adenoviral vector production. Mol Ther 8: 846-852.
35. Evans, JP, Brinkhous, KM, Brayer, GD, Reisner, HM and High, KA (1989). Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA 86: 10095-10099.
36. Brown, BD, Shi, CX, Powell, S, Hurlbut, D, Graham, FL and Lillicrap, D (2004). Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 103: 804-810.
37. McCormack, WM Jr, Seiler, MP, Bertin, TK, Ubhayakar, K, Palmer, DJ, Ng, P et al. (2006). Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. J Thromb Haemost 4: 1218-1225.
38. Bristol, JA, Shirley, P, Idamakanti, N, Kaleko, M and Connelly, S (2000). In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol Ther 2: 223-232.
39. Mátés, L, Chuah, MK, Belay, E, Jerchow, B, Manoj, N, Acosta-Sanchez, A et al. (2009). Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 41: 753-761.
40. Brunetti-Pierri, N, Grove, NC, Zuo, Y, Edwards, R, Palmer, D, Cerullo, V et al. (2009). Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther 20: 479-485.
41. Yant, SR, Wu, X, Huang, Y, Garrison, B, Burgess, SM and Kay, MA (2005). High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 25: 2085-2094.
42. Kirkness, EF, Bafna, V, Halpern, AL, Levy, S, Remington, K, Rusch, DB et al. (2003). The dog genome: survey sequencing and comparative analysis. Science 301: 1898-1903.
43. Lindblad-Toh, K, Wade, CM, Mikkelsen, TS, Karlsson, EK, Jaffe, DB, Kamal, M et al. (2005). Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438: 803-819.
44. Ehrhardt, A, Xu, H and Kay, MA (2003). Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol 77: 7689-7695.
45. Jager, L and Ehrhardt, A (2009). Persistence of high-capacity adenoviral vectors as replication-defective monomeric genomes in vitro and in murine liver. Hum Gene Ther 20: 883-896.
46. Jager, L and Ehrhardt, A (2007). Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther 7: 272-283.
47. Snyder, RO, Miao, C, Meuse, L, Tubb, J, Donahue, BA, Lin, HF et al. (1999). Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 5: 64-70.
48. Xu, L, Gao, C, Sands, MS, Cai, SR, Nichols, TC, Bellinger, DA et al. (2003). Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood 101: 3924-3932.